Jan 13, 07:32 PM

Cytokinetics CEO Robert Blum Confirms $CYTK Is Not Seeking Acquisition Ahead of Heart Drug Launch at JPMorgan Healthcare Conference

Cytokinetics, a biopharmaceutical company, is not seeking to be acquired, according to CEO Robert Blum. He stated that while the company is not for sale, it would not reject potential suitors. Cytokinetics is preparing to launch a new heart drug, which may attract interest from other firms. Blum's comments were reported in an interview with Stat News during the JPMorgan Healthcare Conference.

#Cytokinetics #Robert Blum #Blum #Stat News #JPMorgan Healthcare Conference

Written with ChatGPT (GPT-4o mini).

Sources

John T. Bresnahan@john_bresnahan
2 years ago
did Blum extol a McKinsey white paper X) $cytk https://t.co/sqeLo9jNgC
STAT@statnews
2 years ago
The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors. https://t.co/JrRYYk9zUo
CHItrader@CHItraders
2 years ago
$CYTK Cytokinetics CEO it is not looking to be acquired, according to Stat News, but that doesn’t mean the company would turn away potential suitor

Cytokinetics CEO Robert Blum Confirms $CYTK Is Not Seeking Acquisition Ahead of Heart Drug Launch at JPMorgan Healthcare Conference

Sources

Additional media

Similar Stories